
|Videos|October 21, 2022
Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer
Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.
Advertisement
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
3
Rheumatoid Arthritis Linked to Elevated Pneumonia Risk, Especially in Seropositive Disease
4
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
5